49 results
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
24 Jun 24
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
7:46am
and unpredictable Russia/Ukraine conflict and COVID-19 pandemic delay achievement of those milestones. Further discussion about these and other risks
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
10 May 24
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
8:45am
project, including the risk that the evolving and unpredictable Russia/Ukraine conflict and COVID-19 pandemic delay achievement of those milestones. Further
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
22 Mar 24
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
8:52am
the risk that the evolving and unpredictable Russia/Ukraine conflict and COVID-19 pandemic delay achievement of those milestones. Further discussion
8-K
EX-99.1
ymgbi
18 Mar 24
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
4:05pm
8-K
EX-99.1
n82wzzoqfqqsski4
30 Jan 24
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
5:00pm
8-K
EX-99.1
m889dl
18 Dec 23
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
7:10am
8-K
EX-99.1
cemktvnibl h2b0p8bg6
13 Nov 23
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
5:10pm
8-K
EX-99.1
45j3gm7
3 Oct 23
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
5:00pm
8-K
EX-99.1
2vdovx4mip5svpj x0
14 Aug 23
Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:30pm
8-K
EX-99.1
47vzura5z7 gi5x03
31 Jul 23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
8:28am
424B5
ovxkv7 0ic
31 Jul 23
Prospectus supplement for primary offering
8:23am
8-K
EX-99.1
nzq8 8n1b5vuwtgf
27 Jul 23
55% objective response rate; 23% complete response rate in locally advanced cSCC
7:30am
424B5
putdskykfh9eybeyyxcx
24 May 23
Prospectus supplement for primary offering
5:25pm
8-K
EX-99.1
b93u7jxsor7fkupi
24 May 23
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
5:24pm